Reaction
Chronic Recurrent Multifocal Osteomyelitis reporting signals
As of the last recalculation, Chronic Recurrent Multifocal Osteomyelitis appears in 110 FAERS reports alongside 4 co-occurring drug terms. The strongest observed disproportionality signal is ADALIMUMAB-FKJP (PRR 482.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Adalimumab-Fkjp | 57 | 482.2 | 482.8 |
| Adalimumab-Aaty | 57 | 471.9 | 472.5 |
| Adalimumab-Adaz | 57 | 423.1 | 423.6 |
| Canakinumab | 8 | 150.8 | 150.9 |